


OncoDiscover[®] Circulating Tumor Cells Test enables the detection of disease relapse by monitoring of CTCs post-treatment.



OncoDiscover[®] CTC Test

The OncoDiscover[®] CTC Test is built on the backbone of a proprietary multicomponent in-vitro diagnostic kit (OncoViu[®] Kit) for capturing Circulating Tumor Cells from cancer patient blood.

Validation Data*

Sensitivity	Specificity	Accuracy
94.32%	98%	95.17%

Accreditations/Patents



DCG(I)
License No.
MFG/IVD/2019/000031



ISO 13485:2016 certified
by INTERTEK;
Certificate No. 0140783



'Innovator of the Year 2019'
Department of Biotechnology,
Government of India



Patented
International Application No.
PCT/IB2016/050779

Targeting Antibody
Graphene
Dendrimer (PAMAM)
Glutathione
Iron oxide nanoparticle




Fig 1. Multicomponent CTC capture kit

Diameter = ≈ 350 nm

Circulating Tumor Cells Fugitives on the run




Fig 2. Circulating Tumor Cells (CTC) in peripheral blood**

*Ref: Qayyumi B, Oral Surg Oral Med Oral Pathol Oral Radiol. 2022;134(1):73-83;
** Lucci et al, Lancet Oncology, 2012

Circulating Tumor Cells

Circulating Tumor Cells (CTC) are cells that are shed into the bloodstream by the primary tumor. CTCs have been investigated as **diagnostic, prognostic and predictive** biomarkers in many types of cancer.

CTC serve as seeds for growth of additional tumors (metastasis) in vital distant organs.

CTC counts are associated with unfavorable prognosis in early stage cancer patients.

Circulating Tumor Cell Clusters

CTC clusters are defined as groups of two or more aggregated CTCs found in the blood of patients with solid tumor.

CTC clusters have a **survival advantage** over individual CTCs during their transit in the blood stream and a better **potential for colonization** in the distant sites and can likely contribute to metastasis.

CTC and Minimal Residual Disease (MRD)

Minimal Residual Disease (MRD) can be defined as cancer persisting in a patient after treatment that cannot be detected with current medical imaging modalities and is, therefore, an occult stage of cancer progression.




Fig 3. CTC captured from blood sample of Breast Cancer patient





Fig 4. CTC Cluster captured from blood sample of Mixed Mullerian Cancer patient

- The OncoDiscover® Liquid Biopsy Test detects and characterizes **minimal residual disease (MRD)** by identifying tumor cells shed from the primary lesion.
- Useful even when there are no clinical or radiological signs of metastasis or residual tumor cells.
- Enables **monitoring of circulating tumor cells (CTCs)** during post-treatment follow-up.
- Allows **earlier detection of disease relapse** compared to standard radiological imaging.
- Assesses **PD-L1 and Her2** expression on CTCs to guide targeted therapy.

Detection of Circulating Tumor Cells (CTC) allows monitoring of minimal residual disease and subsequent metastatic progression. Early therapeutic intervention on the basis of liquid biopsy assessments might improve patient outcomes.

Logistics and TAT



Fighting cancer.
One cell at a time.
One in a billion cells.

